

CD40 Protein, Canine, Recombinant (His)

General Information

Synonyms:	CD40 molecule, TNF receptor superfamily member 5
Protein Construction:	Glu21-Ala194
Species:	Canine
Expression Host:	HEK293 Cells
Accession:	Q7YRL5
Molecular Weight:	20.14 kDa (Predicted); 30-40 kDa (Due to glycosylation)

QC Testing

Biological Activity:	Immobilized Canine CD40, His Tag at 5 µg/ml (100 µl/well) on the plate. Dose response curve for Human CD40 Ligand (Trimer) , hFc Tag with the EC50 of 6.5 ng/ml determined by ELISA.
Purity:	> 95% as determined by Tris-Bis PAGE; > 95% as determined by HPLC
Endotoxin:	< 1.0 EU/µg of the protein as determined by the LAL method.
Formulation:	Lyophilized from 0.22µm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.

Preparation and Storage

Reconstitution:

Reconstitute the lyophilized protein in distilled water. The product concentration should not be less than 100 µg/ml. Before opening, centrifuge the tube to collect powder at the bottom. After adding the reconstitution buffer, avoid vortexing or pipetting for mixing.

Stability & Storage:

It is recommended to store recombinant proteins at -20°C to -80°C for future use. Lyophilized powders can be stably stored for over 12 months, while liquid products can be stored for 6-12 months at -80°C. For reconstituted protein solutions, the solution can be stored at -20°C to -80°C for at least 3 months. Please avoid multiple freeze-thaw cycles and store products in aliquots.

Actual storage temperature shall be subject to the COA.

Shipping:

In general, lyophilized powders are shipped with blue ice, while solutions are shipped with dry ice.

Protein Background

CD40 is a costimulatory protein found on antigen presenting cells and is required for their activation. The binding of CD154 (CD40L) on TH cells to CD40 activates antigen presenting cells and induces a variety of downstream effects. CD40 molecule is a potential target for cancer immunotherapy. There are number of completed and ongoing clinical trials where agonistic anti-CD40 monoclonal antibodies are employed to activate an anti-tumor T cell response via activation of dendritic cells.

Reference

van Kooten C, et al. (2000). CD40-CD40 ligand. *J Leukoc Biol.* 67 (1): 2-17.

Bhushan A, et al. (2002). CD40:CD40L interactions in X-linked and non-X-linked hyper-IgM syndromes. *Immunol Res.* 24 (3): 311-24.

Chatzigeorgiou A, et al. (2009) CD40/CD40L signaling and its implication in health and disease. *Biofactors.* 35(6): 474-83.

Li R, et al. (2009) Expression of CD40 and CD40L in Gastric Cancer Tissue and Its Clinical Significance. *Int J Mol Sci.* 10 (9): 3900-17.

Lievens D, et al. (2009) The multi-functionality of CD40L and its receptor CD40 in atherosclerosis. *Thromb Haemost.* 102(2): 206-14.

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel: 781-999-4286 E_mail: info@targetmol.com Address: 34 Washington Street, Wellesley Hills, MA 02481